[Commercial Synthesis Spotlight] Scalable Synthesis of the Key Intermediate of Antibiotic RSC-435830

RSC-435830 (also known as GSK-3342830) is a β-lactam antibiotic featuring a rare C2 (S)-methylcephalosporin motif.

[New Drug Spotlight] Taletrectinib - A Next-Generation ROS1 Inhibitor Targeting Resistant Mutations and Brain Metastases

Taletrectinib (Ibtrozi®; Dovbleron® in China) was approved by China’s NMPA in December 2024 for adult patients with locally advanced or metastatic ROS1-positive NSCLC and received FDA approval on June 11, 2025 for the same indication.

[New Drug Spotlight] Casdatifan - A Second-Generation Oral HIF-2α Inhibitor in Clinical Development for ccRCC

Casdatifan is a second-generation, orally bioavailable HIF-2α inhibitor developed by Arcus Biosciences.

[Commercial Synthesis Spotlight] Kilogram-Scale Synthesis and Impurity Profiling of LY104

LY104 is a novel compound designed as a potential therapeutic for chronic obstructive pulmonary disease (COPD), a severe inflammatory airway condition.

[Commercial Synthesis Spotlight] Scalable Synthesis of the Key Intermediate of Udifitimod (BMS-986166)

Udifitimod (BMS-986166) is a selective sphingosine-1-phosphate receptor 1 (S1PR1) modulator developed for immunological indications such as atopic dermatitis and other autoimmune disorders.

[Commercial Synthesis Spotlight] Scalable Synthesis of Selective PKMYT1 Inhibitor Lunresertib

Lunresertib (RP-6306) is the first selective and orally bioavailable inhibitor of PKMYT1, a serine/threonine kinase that regulates CDK1 activity through phosphorylation.

[Commercial Synthesis Spotlight] Optimization of the Manufacturing Process for Arformoterol

Arformoterol is the (R, R)-enantiomer of formoterol, a highly potent long-acting β₂-adrenergic agonist used primarily for treating respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.

[Commercial Synthesis Spotlight] First-Generation Manufacturing Process of GDC-8264

GDC-8264 is a selective inhibitor of RIPK1 (receptor-interacting protein kinase 1), a key regulator of inflammation and cell death pathways.